期刊文献+

抗VSTM1-v2细胞因子人源化单链抗体文库的构建及筛选

Gene construction and screening of humanized single chain antibody library against VSTM1-v2 cytokine
原文传递
导出
摘要 本文将鼠源VH-CDR3库(library of murine VH-CDR3)移植到特定的人源scFv(single-chain antibody fragment)VH3-VΚ1框架构建人源化scFv文库,快速筛选抗VSTM1-v2的人源化单链抗体。以抗VSTM1-v2鼠源cDNA为模板,扩增出鼠源VH-CDR3库,随后将鼠源VH-CDR3库移植到人源scFv(VH3-VΚ1)上并通过核糖体展示富集抗VSTM1-v2人源化scFv文库,该文库序列通过与原核基因表达调控等成分(N端添加T7启动子、SD序列和PelB序列、C端添加his标签序列和T7 terminal序列)拼接,构建表达型TA载体转化大肠杆菌BL21(DE3)进行可溶性表达。最终构建了一个库容达1012的人源化单链抗体文库,完成了1 000个克隆的初步鉴定,并筛选出EC50达21.35 nmol·L 1的抗VSTM1-v2人源化scFv。该研究结果,一方面获得了具有潜在应用价值的抗-VSTM1-v2先导抗体;另一方面,为快速获得人源化抗体提供了一个新技术途径。 To rapidly select potent anti-VSTMl-v2 scFv (single-chain antibody fragment) by construction and screening of a humanized scFv library in which a murine VH-CDR3 library was grafted onto a human scFv framework. A murine VH-CDR3 library was amplified from anti-VSTMl-v2 murine cDNA and grafted on human scFv (VH3-VK1) framework. Anti-VSTMI-v2 scFv templates were selected and enriched through ribosome display, TA-cloned into expression vector, and transformed into BL21 (DE3) for soluble expression of target scFv. A total of 1 000 clones were randomly picked. Positive ones were first identified using colony PCR, indirect ELISA, Western blotting and then verified with sequencing and dose response ELISA. At last an anti-VSTMl-v2 humanized scFv with good binding affinity (EC s0 = 21.35 nmol'L-1) was selected from the humanized library of 1012 members generated in this study. This scFv antibody might have potential applications. This study provides a new approach for rapid screeninz of humanized antibodies.
出处 《药学学报》 CAS CSCD 北大核心 2013年第11期1651-1656,共6页 Acta Pharmaceutica Sinica
基金 国家"重大新药创制"科技重大专项资助项目(2011ZX09506-005) 中国医药集团新产品基金项目(2011SW12-1)
关键词 VSTM1-v2细胞因子 鼠源VH—CDR3 改良的TA克隆 人源化单链抗体 VSTMI-v2 cytokine murine VH-CDR3 optimized TA-clone humanized scFv
  • 相关文献

参考文献1

二级参考文献11

  • 1马大龙.免疫组学:21世纪免疫学家的新挑战[J].中华微生物学和免疫学杂志,2005,25(9):697-700. 被引量:4
  • 2Jinushi M, Tahara H. Cytokine gene-mediated immunotherapy: current status and future perspectives[J]. Cancer Sci, 2009, 100 (8) : 1389 -1396.
  • 3Neri P, Lettieri M, Fortuna C, et al. Adalimumab (humira^TM) in ophthalmology: a review of the literature [ J ]. Middle East Afr J Ophthalmol, 2010, 17(4) : 290-296.
  • 4Chamuleau ME, van de Loosdrecht AA, Huijgens PC. Monoclonal antibody therapy in haematological malignancies[ J]. Curr Clin Pharmacol, 2010, 5(3): 148-159.
  • 5Flynn JF, Wong C, Wu JM. Anti-EGFR therapy: Mechanism and advances in clinical efficacy in breast cancer [ J ]. J Oncol, 2009, 2009 : 526963.
  • 6Ascierto PA, Marincola FM, Ribas A. Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application [ J ]. J Transl Med, 2011, 9: 196.
  • 7Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti- PD-L1 antibody in patients with advanced cancer[ J]. N Engl J Med, 2012, 366(26): 2455 -2465.
  • 8Guo X, Zhang Y, Wang P, et al. VSTM1-v2, a novel soluble glycoprotein, promotes the differentiation and activation of Th17 cells [ J]. Cell Immunol, 2012, 278( 1 - 2) : 136 - 142.
  • 9Steevels TA, Lebbink R J, Westerlaken GH, et al. Signal inhibitory receptor on leukocytes-1 is a novel functional inhibitory immune receptor expressed on human phagocytes [J]. J Immunol, 2010, 184 (9) : 4741 -4748.
  • 10李婷,郭晓欢,王彧,Markus Plate,邵陆宁,宋泉声,马大龙,韩文玲.抗CMTM4多克隆抗体的制备、纯化和鉴定[J].细胞与分子免疫学杂志,2008,24(1):41-44. 被引量:11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部